FOLH1 and neoplasm: There is now need for a Phase III study with dosimetric data comparing the efficacy of [177Lu]Lu-PSMA-617 to the best available treatment as last-line treatment for metastatic salivary gland carcinoma in order to determine the optimal tumor dose for higher efficacy.